B-hHER2 MC38

Basic Information

Targeting Strategy

Gene targeting strategy for B-hHER2 MC38 cells.

The exogenous CAG promoter and human ERBB2 coding sequence was inserted to replace part of murine exon 2 and all of exons 3-7. The insertion disrupts the endogenous murine Erbb2 gene, resulting in a non-functional transcript.

Protein expression analysis

HER2 expression analysis in B-hHER2 MC38 cells by flow cytometry.

Single cell suspensions from wild-type MC38 and B-hHER2 MC38 cultures were stained with species-specific anti-HER2 antibody. Mouse HER2 was detectable in wild-type MC38 cells. Human HER2 was detected on the surface of B-hHER2 MC38 cells but not wild-type MC38 cells. The 2-B06 clone of B-hHER2 MC38 cells was used for in vivo tumor growth assays.

Tumor growth curve & Body weight changes

Subcutaneous homograft tumor growth of B-hHER2 MC38 cells. 

B-hHER2 MC38 cells (5×10⁵) and wild-type MC38 cells (5×10⁵) were subcutaneously implanted into C57BL/6 mice (female, 7-week-old, n=5). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B)  Body weight (Mean± SEM). Volume was expressed in mm³ using the formula: V=0.5 X long diameter X short diameter². As shown in panel A, B-hHER2 MC38 cells were able to form tumors in vivo and can be used for efficacy studies.

Subcutaneous homograft tumor growth of B-hHER2 MC38 cells. 

B-hHER2 MC38 cells (5×10⁵) and wild-type MC38 cells (5×10⁵) were subcutaneously implanted into heterozygous B-hCD3E/hHER2 mice (female, 7-week-old, n=5). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B)  Body weight (Mean± SEM). Volume was expressed in mm³ using the formula: V=0.5 X long diameter X short diameter². As shown in panel A, B-hHER2 MC38 cells were able to form tumors in vivo and can be used for efficacy studies.

Subcutaneous homograft tumor growth of B-hHER2 MC38 cells. 

B-hHER2 MC38 cells (5×10⁵, 1×10⁶, 5×10⁶) were subcutaneously implanted into homozygous B-hCD3E mice (female, 7-week-old, n=5). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B)  Body weight (Mean± SEM). Volume was expressed in mm³ using the formula: V=0.5 X long diameter X short diameter². As shown in panel A, B-hHER2 MC38 cells were able to form tumors in vivo and can be used for efficacy studies.

Subcutaneous homograft tumor growth of B-hHER2 MC38 cells. 

B-hHER2 MC38 cells (5×10⁵, 1×10⁶, 5×10⁶) were subcutaneously implanted into homozygous B-h4-1BB mice (female, 7-week-old, n=6). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B)  Body weight (Mean± SEM). Volume was expressed in mm³ using the formula: V=0.5 X long diameter X short diameter². As shown in panel A, B-hHER2 MC38 cells were able to form tumors in vivo and can be used for efficacy studies.

Subcutaneous homograft tumor growth of B-hHER2 MC38 cells. 

B-hHER2 MC38 cells (5×10⁵, 1×10⁶, 5×10⁶, 1×107) were subcutaneously implanted into homozygous B-h4-1BB/hHER2 mice (female, 11-week-old, n=6). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B)  Body weight (Mean± SEM). Volume was expressed in mm³ using the formula: V=0.5 X long diameter X short diameter². As shown in panel A, B-hHER2 MC38 cells were able to form tumors in vivo and can be used for efficacy studies.

Protein expression analysis of tumor cells

B-hHER2 MC38 cells were subcutaneously transplanted into C57BL/6 mice (n=5), and on 35 days post inoculation, tumor cells were harvested and assessed for human HER2 expression by flow cytometry. As shown, human HER2 was highly expressed on the surface of tumor cells. Therefore, B-hHER2 MC38 cells can be used for in vivo efficacy studies of HER2 therapeutics.

B-hHER2 MC38 cells were subcutaneously transplanted into B-hCD3E mice (n=5), and on 35 days post inoculation, tumor cells were harvested and assessed for human HER2 expression by flow cytometry. As shown, human HER2 was highly expressed on the surface of tumor cells. Therefore, B-hHER2 MC38 cells can be used for in vivo efficacy studies of HER2 therapeutics.